Diagnostics company Immunovia (Nasdaq Stockholm: IMMNOV) reported on Monday that it is continuing to commercialise its IMMray PanCan-d test in the US with the appointment of a new national sales director by its US subsidiary, Immunovia Inc.
The company's IMMray PanCan-d test is the world's first blood test dedicated to the early detection of pancreatic cancer.
Commercialization of IMMray PanCan-d started in August 2021 in the US. The test is offered as a laboratory developed test (LDT) exclusively through Immunovia Inc.
Immunovia added that Jon Hager starts in his position of national sales director on 5 December 2022.
Hager worked at Myriad Genetics where he was a core member of the team that launched hereditary cancer testing to gynecologists.
Innate Pharma receives HSR clearance for expansion of collaboration with Sanofi on NK Cell Engagers
ImmPACT Bio USA's IMPT-314 IND application receives US FDA approval